Last 12 months
Inside the activity.
0 purchase rows · 46 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 15 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2017 Filed Sep 15, 2017 20:31 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 625 | $123.15 | $76,968.75 |
DisclosureSEC source: 0001209191-17-052984 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,540 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 16,777 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:28 UTC |
Siegel Eric H.EVP, General Counsel
|
Tax withholdingCommon Stock | 680 | $123.15 | $83,742.00 |
DisclosureSEC source: 0001209191-17-052981 · doc4.xml · nonDerivative · entry 1 Siegel Eric H. · CIK 0001527573 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,053 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:19 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
Tax withholdingCommon Stock | 2,486 | $123.15 | $306,150.90 |
DisclosureSEC source: 0001209191-17-052964 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,506 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 252,916 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:24 UTC |
Huber Reid MEVP, Chief Scientific Officer
|
Tax withholdingCommon Stock | 692 | $123.15 | $85,219.80 |
DisclosureSEC source: 0001209191-17-052975 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,862 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:14 UTC |
GRYSKA DAVID WExecutive Vice President, CFO
|
Tax withholdingCommon Stock | 712 | $123.15 | $87,682.80 |
DisclosureSEC source: 0001209191-17-052957 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,820 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 21,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:11 UTC |
Flannelly Barry PEVP & General Manager US
|
Tax withholdingCommon Stock | 674 | $123.15 | $83,003.10 |
DisclosureSEC source: 0001209191-17-052954 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,496 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| September 08, 2017 Filed Sep 8, 2017 21:06 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
|
PurchaseCommon Stock | 2,029 | $132.00 | $267,828.00 |
DisclosureSEC source: 0001638599-17-000926 · doc4_4960.xml · nonDerivative · entry 6 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 789,416 F4 · ownership.nature: On September 8, 2017, 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159 ("14159", and together with 667 and Life Sciences the "Funds") purchased 12,569, 85,402 and 2,029 shares of the Common Stock, respectively of the Issuer, pursuant to an underwritten public offering. F6 · ownership.nature: Includes beneficial ownership of 1,710 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 95,000 shares received previously from exercise of 95,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F8 · ownership.nature: After giving effect to the transactions reported herein and as a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 789,416 shares of common stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. F9 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| September 08, 2017 Filed Sep 8, 2017 21:06 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
|
PurchaseCommon Stock | 85,402 | $132.00 | $11,273,064.00 |
DisclosureSEC source: 0001638599-17-000926 · doc4_4960.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 29,247,347 F4 · ownership.nature: On September 8, 2017, 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159 ("14159", and together with 667 and Life Sciences the "Funds") purchased 12,569, 85,402 and 2,029 shares of the Common Stock, respectively of the Issuer, pursuant to an underwritten public offering. F6 · ownership.nature: Includes beneficial ownership of 1,710 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 95,000 shares received previously from exercise of 95,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F7 · ownership.nature: After giving effect to the transactions reported herein and as a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest 29,247,347 shares of common stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F9 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| September 08, 2017 Filed Sep 8, 2017 21:06 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
|
PurchaseCommon Stock | 12,569 | $132.00 | $1,659,108.00 |
DisclosureSEC source: 0001638599-17-000926 · doc4_4960.xml · nonDerivative · entry 4 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,386,818 F4 · ownership.nature: On September 8, 2017, 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159 ("14159", and together with 667 and Life Sciences the "Funds") purchased 12,569, 85,402 and 2,029 shares of the Common Stock, respectively of the Issuer, pursuant to an underwritten public offering. F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 4,386,818 shares of common stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F6 · ownership.nature: Includes beneficial ownership of 1,710 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 95,000 shares received previously from exercise of 95,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F9 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:04 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-17-051866 · doc4.xml · derivative · entry 3 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,187 Underlying: Common Stock · 3,000 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:04 UTC |
Trower PaulPrincipal Accounting Officer
|
SaleCommons Stock | 3,000 | $138.41 | $415,230.00 |
DisclosureSEC source: 0001209191-17-051866 · doc4.xml · nonDerivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,853 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $138.09 - $138.50. F4 · balance_after: This includes an 4,977 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:04 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 3,000 | $17.79 | $53,370.00 |
DisclosureSEC source: 0001209191-17-051866 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 20:27 UTC |
Siegel Eric H.EVP, General Counsel
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,820 | $0.00 Strike: $64.55 | $0.00 |
DisclosureSEC source: 0001209191-17-051290 · doc4.xml · derivative · entry 3 Siegel Eric H. · CIK 0001527573 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,932 Underlying: Common Stock · 1,820 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 20:27 UTC |
Siegel Eric H.EVP, General Counsel
|
SaleCommon Stock | 1,820 | $137.40 | $250,068.00 |
DisclosureSEC source: 0001209191-17-051290 · doc4.xml · nonDerivative · entry 2 Siegel Eric H. · CIK 0001527573 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,733 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested and 1,388 shares of common stock issuable pursuant to previously reported restricted stock units that have vested but have not yet been delivered to the reporting person. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 20:27 UTC |
Siegel Eric H.EVP, General Counsel
|
Exercise / conversionCommon Stock | 1,820 | $64.55 | $117,481.00 |
DisclosureSEC source: 0001209191-17-051290 · doc4.xml · nonDerivative · entry 1 Siegel Eric H. · CIK 0001527573 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 20:22 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-17-051286 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,900 Underlying: Common Stock · 20,000 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 20:22 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 20,000 | $140.00 | $2,800,000.00 |
DisclosureSEC source: 0001209191-17-051286 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,067 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: This includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested and 1,388 shares of common stock issuable pursuant to previously reported restricted stock units that have vested but have not yet been delivered to the reporting person. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 20:22 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 20,000 | $17.79 | $355,800.00 |
DisclosureSEC source: 0001209191-17-051286 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 397 | $0.00 Strike: $83.83 | $0.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · derivative · entry 9 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,326 Underlying: Common Stock · 397 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,192 | $0.00 Strike: $88.68 | $0.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · derivative · entry 8 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,495 Underlying: Common Stock · 1,192 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning March 2, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 522 | $0.00 Strike: $95.76 | $0.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · derivative · entry 7 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,348 Underlying: Common Stock · 522 shares Expires 2023-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 7, 2016, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
SaleCommon Stock | 397 | $125.00 | $49,625.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,165 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 16,777 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
SaleCommon Stock | 1,192 | $125.00 | $149,000.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,562 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
SaleCommon Stock | 522 | $125.00 | $65,250.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,754 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 397 | $83.83 | $33,280.51 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 1,192 | $88.68 | $105,706.56 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 522 | $95.76 | $49,986.72 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 20:33 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-17-047893 · doc4.xml · derivative · entry 4 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,187 Underlying: Common Stock · 3,000 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 20:33 UTC |
Trower PaulPrincipal Accounting Officer
|
SaleCommons Stock | 3,000 | $125.25 | $375,750.00 |
DisclosureSEC source: 0001209191-17-047893 · doc4.xml · nonDerivative · entry 3 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,853 F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $123.99 - $126.13. F5 · balance_after: This includes an 4,977 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 20:33 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 3,000 | $17.79 | $53,370.00 |
DisclosureSEC source: 0001209191-17-047893 · doc4.xml · nonDerivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:33 UTC |
Trower PaulPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 295 | $125.98 | $37,164.10 |
DisclosureSEC source: 0001209191-17-047893 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,853 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:54 UTC |
Siegel Eric H.EVP, General Counsel
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,820 | $0.00 Strike: $64.55 | $0.00 |
DisclosureSEC source: 0001209191-17-047393 · doc4.xml · derivative · entry 3 Siegel Eric H. · CIK 0001527573 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,752 Underlying: Common Stock · 1,820 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:54 UTC |
Siegel Eric H.EVP, General Counsel
|
SaleCommon Stock | 1,820 | $132.92 | $241,914.40 |
DisclosureSEC source: 0001209191-17-047393 · doc4.xml · nonDerivative · entry 2 Siegel Eric H. · CIK 0001527573 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,733 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested and 1,388 shares of common stock issuable pursuant to previously reported restricted stock units that have vested but have not yet been delivered to the reporting person. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:54 UTC |
Siegel Eric H.EVP, General Counsel
|
Exercise / conversionCommon Stock | 1,820 | $64.55 | $117,481.00 |
DisclosureSEC source: 0001209191-17-047393 · doc4.xml · nonDerivative · entry 1 Siegel Eric H. · CIK 0001527573 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 522 | $0.00 Strike: $95.76 | $0.00 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · derivative · entry 9 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,870 Underlying: Common Stock · 522 shares Expires 2023-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Beginning January 7, 2016, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,772 | $0.00 Strike: $83.83 | $0.00 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · derivative · entry 8 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,723 Underlying: Common Stock · 4,772 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,191 | $0.00 Strike: $88.68 | $0.00 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · derivative · entry 7 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,687 Underlying: Common Stock · 1,191 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning March 2, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
SaleCommon Stock | 522 | $131.09 | $68,428.98 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,165 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $129.57 - $132.10. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · balance_after: This includes an 18,165 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
SaleCommon Stock | 4,772 | $131.09 | $625,561.48 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,687 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $129.57 - $132.10. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
SaleCommon Stock | 1,191 | $131.09 | $156,128.19 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,459 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $129.57 - $132.10. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 522 | $95.76 | $49,986.72 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 4,772 | $83.83 | $400,036.76 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 1,191 | $88.68 | $105,617.88 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:03 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantIncentive Stock Option (right to buy) · Derivative | 779 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044427 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779 Underlying: Common Stock · 779 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:03 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,349 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044427 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,349 Underlying: Common Stock · 11,349 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:03 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantCommon Stock | 3,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044427 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,170 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Flannelly's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:02 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-17-044425 · doc4.xml · derivative · entry 6 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,187 Underlying: Common Stock · 3,000 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:02 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantIncentive Stock Option (right to buy) · Derivative | 216 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044425 · doc4.xml · derivative · entry 5 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216 Underlying: Common Stock · 216 shares Expires 2027-07-04 F6 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:02 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,539 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044425 · doc4.xml · derivative · entry 4 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,539 Underlying: Common Stock · 2,539 shares Expires 2027-07-04 F6 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:02 UTC |
Trower PaulPrincipal Accounting Officer
|
SaleCommon Stock | 3,000 | $126.18 | $378,540.00 |
DisclosureSEC source: 0001209191-17-044425 · doc4.xml · nonDerivative · entry 3 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,148 F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $125.47 - $126.76. F4 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F5 · balance_after: Includes an aggregate of 4,380 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.